Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden
- 1 December 2004
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 22 (17) , 1153-1165
- https://doi.org/10.2165/00019053-200422170-00005
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Health-related quality of life after osteoporotic fracturesOsteoporosis International, 2004
- Cost Effectiveness of Alendronate (Fosamax??) for the Treatment of Osteoporosis and Prevention of FracturesPharmacoEconomics, 2003
- Health-Related Quality of Life in Postmenopausal Women With Low BMD With or Without Prevalent Vertebral FracturesJournal of Bone and Mineral Research, 2000
- Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical SynthesisJournal of Bone and Mineral Research, 2000
- US and UK health economics: Two disciplines separated by a common language?Health Economics, 1998
- Accounting for future costs in medical cost-effectiveness analysisJournal of Health Economics, 1997
- Cost-effectiveness of Fracture Prevention in Established OsteoporosisScandinavian Journal of Rheumatology, 1996
- The Cost Effectiveness of Hypertension Treatment in SwedenPharmacoEconomics, 1995
- Hip fractures in the elderly: A world-wide projectionOsteoporosis International, 1992
- Bone-density measurementThe Lancet, 1992